Lercanidipino Viatris

Lercanidipine, the active ingredient in Lercanidipino Viatris, is a calcium channel blocker presented as an oral tablet for oral use. It is indicated for the management of hypertension in adult patients. GNH USA supplies Lercanidipino Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine is a dihydropyridine calcium‑channel blocker used to treat conditions related to elevated arterial pressure.

Hypertension: lowers systolic and diastolic blood pressure in patients with primary hypertension.

Lercanidipine may be associated with a range of adverse reactions. Patients should be informed of both frequent and uncommon events.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: warmth and redness, typically occurring shortly after dosing. - Peripheral edema: swelling of the ankles or feet. - Dizziness or light‑headedness, especially when standing quickly. - Tachycardia or palpitations.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Angioedema: swelling of face, lips, tongue, or throat. - Myocardial infarction: chest pain or discomfort suggestive of heart attack. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Anaphylactic reaction: rapid onset of breathing difficulty, hives, or shock.

Before initiating therapy with lercanidipine, clinicians should consider several safety aspects. - Blood pressure monitoring: ensure adequate control and avoid excessive hypotension. - Hepatic impairment: dose adjustment may be required in patients with liver dysfunction. - Elderly patients: start at the lowest effective dose and monitor for orthostatic effects. - Concomitant antihypertensives: assess risk of additive blood‑pressure lowering. - Severe hypotension: contraindicated in patients with markedly low blood pressure. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension. - Co‑administration with other potent antihypertensives: can cause excessive blood‑pressure reduction.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug exposure and reduce effectiveness. - Grapefruit juice: can raise lercanidipine levels, enhancing side effects. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive response. - Diuretics: may increase risk of electrolyte disturbances when combined. - Beta‑blockers: monitor for additive bradycardia or AV‑block.